Klf5 and eIF5a suppress Ang II–induced expression of NOX1 in VSMCs. by Dong Ma (584680)

Subjects:

Phlorizin decreased renal GTTR uptake, and increased serum drug levels <i>in vivo</i>. by Meiyan Jiang (438439)

Image 9_Behavioral and biochemical changes associated with the analgesic effects of (2R,6R)-hydroxynorketamine alone and in combination with meloxicam following disk puncture in mi... by Vaskar Das (21529538)

“…Our finding supports further study of the clinical potential of (2R,6R)-Hydroxynorketamine as a non-opioid analgesic for discogenic back pain.…”

Image 8_Behavioral and biochemical changes associated with the analgesic effects of (2R,6R)-hydroxynorketamine alone and in combination with meloxicam following disk puncture in mi... by Vaskar Das (21529538)

“…Our finding supports further study of the clinical potential of (2R,6R)-Hydroxynorketamine as a non-opioid analgesic for discogenic back pain.…”

Image 7_Behavioral and biochemical changes associated with the analgesic effects of (2R,6R)-hydroxynorketamine alone and in combination with meloxicam following disk puncture in mi... by Vaskar Das (21529538)

“…Our finding supports further study of the clinical potential of (2R,6R)-Hydroxynorketamine as a non-opioid analgesic for discogenic back pain.…”

Data Sheet 11_Behavioral and biochemical changes associated with the analgesic effects of (2R,6R)-hydroxynorketamine alone and in combination with meloxicam following disk puncture... by Vaskar Das (21529538)

“…Our finding supports further study of the clinical potential of (2R,6R)-Hydroxynorketamine as a non-opioid analgesic for discogenic back pain.…”

Data Sheet 2_Behavioral and biochemical changes associated with the analgesic effects of (2R,6R)-hydroxynorketamine alone and in combination with meloxicam following disk puncture... by Vaskar Das (21529538)

“…Our finding supports further study of the clinical potential of (2R,6R)-Hydroxynorketamine as a non-opioid analgesic for discogenic back pain.…”

Data Sheet 1_Behavioral and biochemical changes associated with the analgesic effects of (2R,6R)-hydroxynorketamine alone and in combination with meloxicam following disk puncture... by Vaskar Das (21529538)

“…Our finding supports further study of the clinical potential of (2R,6R)-Hydroxynorketamine as a non-opioid analgesic for discogenic back pain.…”

Data Sheet 3_Behavioral and biochemical changes associated with the analgesic effects of (2R,6R)-hydroxynorketamine alone and in combination with meloxicam following disk puncture... by Vaskar Das (21529538)

“…Our finding supports further study of the clinical potential of (2R,6R)-Hydroxynorketamine as a non-opioid analgesic for discogenic back pain.…”

Data Sheet 10_Behavioral and biochemical changes associated with the analgesic effects of (2R,6R)-hydroxynorketamine alone and in combination with meloxicam following disk puncture... by Vaskar Das (21529538)

“…Our finding supports further study of the clinical potential of (2R,6R)-Hydroxynorketamine as a non-opioid analgesic for discogenic back pain.…”

Image 6_Behavioral and biochemical changes associated with the analgesic effects of (2R,6R)-hydroxynorketamine alone and in combination with meloxicam following disk puncture in mi... by Vaskar Das (21529538)

“…Our finding supports further study of the clinical potential of (2R,6R)-Hydroxynorketamine as a non-opioid analgesic for discogenic back pain.…”

Data Sheet 1_Behavioral and biochemical changes associated with the analgesic effects of (2R,6R)-hydroxynorketamine alone and in combination with meloxicam following disk puncture... by Vaskar Das (21529538)

“…Our finding supports further study of the clinical potential of (2R,6R)-Hydroxynorketamine as a non-opioid analgesic for discogenic back pain.…”

Data Sheet 4_Behavioral and biochemical changes associated with the analgesic effects of (2R,6R)-hydroxynorketamine alone and in combination with meloxicam following disk puncture... by Vaskar Das (21529538)

“…Our finding supports further study of the clinical potential of (2R,6R)-Hydroxynorketamine as a non-opioid analgesic for discogenic back pain.…”

Loss-of-function of Mp<i>RTN4IP1L</i> confers resistance to thaxtomin A. by Chloe Casey (14341756)

<i>prx-5/6</i> mutations likely cause a decrease in mmBCFA degradation. by Rencheng Wang (463927)

“…<i>elo-5</i>(<i>lf</i>)<i>; Ex</i>[<i>elo-6</i>] is a transgenic strain that significantly overexpressed the <i>elo-6</i> gene and was not sufficient to suppress the L1 arrest phenotype of <i>elo-5</i>(<i>lf</i>). …”

HAstV-1 infection leads to a decrease in epithelial markers while increasing mesenchymal markers. by Virginia Hargest (12447014)

CYP3A94 activity is significantly increased in V79-CYP3A94/DD-POR cells, but decreases after incubation with Shield-1. by Ramona Dettwiler (664360)

Supplementary Material for: Adjunctive active vitamin D (AVD) decreases kidney function during treatment of secondary hyperparathyroidism (SHPT) with extended-release calcifediol (... by figshare admin karger (2628495)

Gut richness and diversity decrease significantly by week 5 of chemoradiotherapy. by Molly B. El Alam (10231830)

Representative fluorescent records of IntegriSense 680^® dye-labeled αvβ3 integrin in control and cetrorelix-treated non-pregnant rats. by Kalman F. Szucs (19353218)

“…Cetrorelix treatment reduced αvβ3 integrin expression, which caused a significant decrease in intensity (bottom image row). …”